| 1.33 0 (0%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.87  |
1-year : | 2.14 |
| Resists | First : | 1.6 |
Second : | 1.84 |
| Pivot price | 1.38 |
|||
| Supports | First : | 1.22 | Second : | 1.01 |
| MAs | MA(5) : | 1.31  |
MA(20) : | 1.46 |
| MA(100) : | 1.25 |
MA(250) : | 1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 15 |
| RSI | RSI(14): 40.6 | |||
| 52-week | High : | 4.75 | Low : | 0.24 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FEMY ] has closed above bottom band by 38.3%. Bollinger Bands are 7.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.34 - 1.35 | 1.35 - 1.35 |
| Low: | 1.25 - 1.26 | 1.26 - 1.27 |
| Close: | 1.32 - 1.33 | 1.33 - 1.34 |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Wed, 03 Apr 2024
Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt? - Simply Wall St
Thu, 28 Mar 2024
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update - Yahoo Finance
Thu, 21 Mar 2024
Premarket Mover: Femasys Inc (FEMY) Up 2.22% - InvestorsObserver
Wed, 13 Mar 2024
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 - GlobeNewswire
Wed, 28 Feb 2024
Femasys Reveals Corporate Update and FDA-Cleared Infertility Solution - TipRanks.com - TipRanks
Fri, 09 Feb 2024
Premarket Mover: Femasys Inc (FEMY) Down 2.90% - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 1.987e+007 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 500 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.402e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 87.8 % |
| Return on Equity (ttm) | -40.7 % |
| Qtrly Rev. Growth | 1.07e+006 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.69 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 18.65 |
| Price to Cash Flow | -4.68 |
| Dividend | 0 |
| Forward Dividend | 1.74e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|